肌酸单酸对帕金森病患者临床进展的影响:一项随机临床试验
, Karl Kieburtz1, Barbara C Tilley2
1University of Rochester, Rochester, New York.
JAMA
|February 11, 2015
概括
在五年内,肌酸单酸在早期帕金森病患者中没有减缓临床衰退. 这项研究不支持使用肌酸治疗帕金森病.
科学领域:
- 神经学 神经学
- 神经退行性疾病 神经退行性疾病
- 临床试验 临床试验
背景情况:
- 帕金森病 (PD) 缺乏减缓进展的治疗方法,这对全球健康造成了重大负担.
- 国家神经疾病和中风研究所建立了帕金森病探索性试验计划,以寻找新的治疗方法.
研究的目的:
- 为了评估肌酸单酸是否比安慰剂更有效地减缓帕金森病患者的长期临床衰退.
主要方法:
- 一个多中心,双盲,安慰剂对照试验随机对1741名帕金森病早期患者进行安慰剂或肌酸 (10g/d).
- 参与者被跟踪至少5年,用临床状况的措施评估结果,包括修改的兰金度量表和日常生活活动.
主要成果:
- 在对955名参与者的临时分析 (中位数随访:4年) 之后,试验因徒劳而提前终止.
- 在肌酸和安慰剂组之间没有观察到临床衰退的显著差异 (P=.45).
- 不良事件在两组之间没有显著差异.
结论:
- 与安慰剂相比,长期的肌酸单治疗没有改善早期治疗的帕金森病患者的临床结果.
- 这些发现不支持使用肌酸单水化合物来治疗帕金森病.
相关概念视频
Parkinson's Disease: Treatment
1.4K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.4K
Parkinson's Disease: Overview
2.5K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.5K
Parkinson Disease ll: Pathophysiology
3
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
3
Parkinson Disease l: Introduction
3
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of...
3
Alterations in Muscle Tone lll
3
Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...
3
Drug Dosing in Renal Diseases: Measurement of Serum Creatinine Concentration and Clearance
360
In healthy individuals, serum creatinine levels remain stable due to a balance between its constant production—primarily from muscle metabolism—and renal excretion. Creatinine is freely filtered by the glomeruli, making it a valuable marker for estimating renal function. When the glomerular filtration rate (GFR) decreases, the kidneys can only eliminate less creatinine, causing serum levels to rise.Serum creatinine concentration is widely used to estimate creatinine clearance...
360


